Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Halozyme Therapeutics stock | $39.51

Own Halozyme Therapeutics stock in just a few minutes.

Fact checked

Halozyme Therapeutics, Inc is a biotechnology business based in the US. Halozyme Therapeutics shares (HALO) are listed on the NASDAQ and all prices are listed in US Dollars. Halozyme Therapeutics employs 132 staff and has a trailing 12-month revenue of around USD$199.6 million.

How to buy shares in Halozyme Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Halozyme Therapeutics. Find the stock by name or ticker symbol: HALO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Halozyme Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$39.51, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Halozyme Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Halozyme Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Halozyme Therapeutics share price

Use our graph to track the performance of HALO stocks over time.

Halozyme Therapeutics shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$39.51
52-week rangeUSD$12.71 - USD$44.53
50-day moving average USD$40.4253
200-day moving average USD$30.7371
Wall St. target priceUSD$41.25
PE ratio 278.6364
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.154

Buy Halozyme Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Forex
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Public
$0
Stocks, ETFs
N/A
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Halozyme Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Halozyme Therapeutics price performance over time

Historical closes compared with the close of $39.51 from 2020-12-09

1 week (2021-01-15) -16.70%
1 month (2020-12-23) -7.36%
3 months (2020-10-23) 27.04%
6 months (2020-07-22) 42.12%
1 year (2020-01-22) 102.10%
2 years (2019-01-22) 148.33%
3 years (2018-01-22) 108.50%
5 years (2016-01-22) 280.64%

Is Halozyme Therapeutics under- or over-valued?

Valuing Halozyme Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Halozyme Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Halozyme Therapeutics's P/E ratio

Halozyme Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 279x. In other words, Halozyme Therapeutics shares trade at around 279x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Halozyme Therapeutics's EBITDA

Halozyme Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$64.7 million.

The EBITDA is a measure of a Halozyme Therapeutics's overall financial performance and is widely used to measure a its profitability.

Halozyme Therapeutics financials

Revenue TTM USD$199.6 million
Operating margin TTM 31.56%
Gross profit TTM USD$26.8 million
Return on assets TTM 8.8%
Return on equity TTM 12.5%
Profit margin 10.79%
Book value $0.732
Market capitalisation USD$5.8 billion

TTM: trailing 12 months

Shorting Halozyme Therapeutics shares

There are currently 15.5 million Halozyme Therapeutics shares held short by investors – that's known as Halozyme Therapeutics's "short interest". This figure is 7% down from 16.6 million last month.

There are a few different ways that this level of interest in shorting Halozyme Therapeutics shares can be evaluated.

Halozyme Therapeutics's "short interest ratio" (SIR)

Halozyme Therapeutics's "short interest ratio" (SIR) is the quantity of Halozyme Therapeutics shares currently shorted divided by the average quantity of Halozyme Therapeutics shares traded daily (recently around 1.3 million). Halozyme Therapeutics's SIR currently stands at 11.46. In other words for every 100,000 Halozyme Therapeutics shares traded daily on the market, roughly 11460 shares are currently held short.

However Halozyme Therapeutics's short interest can also be evaluated against the total number of Halozyme Therapeutics shares, or, against the total number of tradable Halozyme Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Halozyme Therapeutics's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Halozyme Therapeutics shares in existence, roughly 110 shares are currently held short) or 0.1287% of the tradable shares (for every 100,000 tradable Halozyme Therapeutics shares, roughly 129 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Halozyme Therapeutics.

Find out more about how you can short Halozyme Therapeutics stock.

Halozyme Therapeutics share dividends

We're not expecting Halozyme Therapeutics to pay a dividend over the next 12 months.

Halozyme Therapeutics share price volatility

Over the last 12 months, Halozyme Therapeutics's shares have ranged in value from as little as $12.71 up to $44.53. A popular way to gauge a stock's volatility is its "beta".

HALO.US volatility(beta: 1.76)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Halozyme Therapeutics's is 1.7622. This would suggest that Halozyme Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Halozyme Therapeutics overview

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; and National Institute of Allergy and Infectious Diseases. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site